Ginkgo Bioworks (DNA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.75
- EPS estimate
- −$0.90
- EPS surprise
- +16.20%
- Revenue surprise
- −16.19%
- Revenue
- $20.2M
- Revenue estimate
- $24.1M
- Reported
- Aug 5, 2026
Ginkgo Bioworks reported Q2 2026 results on August 5, 2026. It posted a loss of $0.75 per share, narrower than the $0.90 loss expected, a 16.20% beat. Revenue of $20.2 million came in 16.19% below the $24.1 million consensus. Compared with Q2 2025, the loss narrowed from $1.10 per share, while revenue fell about 59% from $49.6 million.
Every quarter in the table, back to Q3 2021, was a loss. The annual loss per share narrowed from $51.60 in 2022 to $18.80 in 2023, $10.68 in 2024 and $5.64 in 2025, and Q2 2026 was the smallest quarterly loss shown. Revenue has fallen at the same time. Annual revenue dropped from $477.7 million in 2022 to $169.7 million in 2025, about 64% lower, and the first half of 2026 brought $39.7 million, against $97.9 million a year earlier. Results against estimates have been uneven, with six beats in the last 20 quarters.
Past Q3 reports came between November 6 and November 15. That points to early or mid-November 2026 for the next report, which will show whether losses keep narrowing as revenue runs near $20 million a quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.90 | −$0.75 | +16.20% | $20.2M | SEC |
| Q1 2026 | May 7, 2026 | −$1.21 | −$1.39 | −14.76% | $19.5M | SEC |
| Q4 2025 | Feb 26, 2026 | −$1.46 | −$1.41 | +3.09% | $33.0M | SEC |
| Q3 2025 | Nov 6, 2025 | −$1.24 | −$1.45 | −16.81% | $38.8M | SEC |
| Q2 2025 | Aug 7, 2025 | −$1.57 | −$1.10 | +29.79% | $49.6M | SEC |
| Q1 2025 | May 6, 2025 | −$1.53 | −$1.68 | −9.55% | $48.3M | SEC |
| Q4 2024 | Feb 25, 2025 | −$1.50 | −$2.00 | −32.98% | $43.8M | SEC |
| Q3 2024 | Nov 12, 2024 | −$2.73 | −$1.08 | +60.41% | $89.0M | SEC |
| Q2 2024 | Aug 8, 2024 | −$3.10 | −$4.40 | −42.05% | $56.2M | SEC |
| Q1 2024 | May 9, 2024 | −$3.33 | −$3.20 | +4.00% | $37.9M | SEC |
| Q4 2023 | Feb 29, 2024 | −$3.87 | −$4.40 | −13.79% | $34.8M | SEC |
| Q3 2023 | Nov 8, 2023 | −$3.66 | −$6.40 | −75.00% | $55.4M | SEC |
| Q2 2023 | Aug 9, 2023 | −$3.45 | −$3.60 | −4.35% | $80.6M | SEC |
| Q1 2023 | May 10, 2023 | −$3.40 | −$4.40 | −29.43% | $80.7M | SEC |
| Q4 2022 | Mar 1, 2023 | −$8.33 | −$4.00 | +51.95% | $98.3M | SEC |
| Q3 2022 | Nov 14, 2022 | −$10.47 | −$16.40 | −56.69% | $66.4M | SEC |
| Q2 2022 | Aug 15, 2022 | −$7.33 | −$16.40 | −123.85% | $144.6M | SEC |
| Q1 2022 | May 16, 2022 | −$8.56 | −$14.80 | −72.86% | $168.4M | SEC |
| Q4 2021 | Mar 28, 2022 | −$1.66 | −$44.00 | −2555.24% | $148.5M | SEC |
| Q3 2021 | Nov 15, 2021 | −$1.40 | −$3.20 | −128.57% | $77.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Ginkgo Bioworks (DNA) last report earnings?
Ginkgo Bioworks last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did DNA beat earnings estimates?
Yes. Ginkgo Bioworks reported EPS of −$0.75 for Q2 2026 against a −$0.90 estimate — a 16.20% beat.
How much revenue did DNA report last quarter?
Ginkgo Bioworks reported $20.2M in revenue for Q2 2026, against a consensus estimate of $24.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.